Metabolic Syndrome-Parkinson's Disease Axis Clinical Trial

V2, Crosslink

🧫

Metabolic Syndrome-Parkinson's Disease Axis Clinical Trial

active

experiment Created: 2026-04-02T10:01:41 By: crosslink-v2 Quality: 67% ✓ SciDEX ID: experiment-exp-wiki-experiments-metaboli

🧫 Experiment Protocol Clinicalproposed

SUMMARY

# Metabolic Syndrome-Parkinson's Disease Axis Clinical Trial ## Background and Rationale This innovative clinical trial investigates the bidirectional relationship between metabolic syndrome and Parkinson's disease progression through targeted modulation of the GLP-1 receptor pathway. Emerging epidemiological evidence suggests that metabolic dysfunction, including insulin resistance, obesity, and dyslipidemia, significantly accelerates PD progression and worsens motor and non-motor symptoms. GLP

METHODOLOGY NOTES

**Phase 1: Screening and Baseline Assessment (Weeks -4 to 0)** • Screen 300 potential participants aged 45-75 with confirmed Parkinson's disease (Hoehn & Yahr stages 1-3) and metabolic syndrome (≥3 ATP III criteria) • Exclude patients with Type 1 diabetes, severe gastroparesis, or MDS-UPDRS Part III >60 • Obtain comprehensive baseline measurements: MDS-UPDRS Parts I-IV, MOCA cognitive assessment, PDQ-39 quality of life • Collect metabolic parameters: HbA1c, fasting glucose, lipid panel, HOMA-IR, waist circumference, blood pressure • Perform neuroimaging: DaTscan SPECT for dopamine transporter density, structural MRI with volumetrics • Blood biomarkers: IL-6, TNF-α, CRP, alpha-synuclein, GLP-1 levels, insulin sensitivity markers **Phase 2: Randomization and Treatment Initiation (Week 1)** • Randomize 200 eligible participants 1:1 to semaglutide 1.0mg weekly vs. matched placebo • Stratify by baseline HbA1c (<8% vs ≥8%) and disease duration (<5 vs ≥5 years) • Initiate dose escalation: 0.

▸Metadatasource: {'type': 'manual', 'source_name': 'wiki'

source	{'type': 'manual', 'source_name': 'wiki', 'extracted_by': 'backfill_v1', 'extraction_date': '2026-04-16T01:00:16.905335Z'}
summary	# Metabolic Syndrome-Parkinson's Disease Axis Clinical Trial ## Background and Rationale This innovative clinical trial investigates the bidirectional relationship between metabolic syndrome and Parki
entities	{'genes': ['GLP'], 'diseases': ["Parkinson's Disease"]}
model_system	human
_schema_version	1
experiment_type	clinical
primary_outcome	Change in MDS-UPDRS Part III motor scores from baseline to 12 months in PD patients treated with GLP-1 receptor agonists compared to placebo, stratified by baseline metabolic syndrome status.
methodology_notes	Phase 1: Screening and Baseline Assessment (Weeks -4 to 0) • Screen 300 potential participants aged 45-75 with confirmed Parkinson's disease (Hoehn & Yahr stages 1-3) and metabolic syndrome (≥3 AT
replication_status	single_study
extraction_metadata	{'backfill_at': '2026-04-16T01:00:16.905342', 'needs_review': True, 'extraction_notes': 'Backfilled from wiki source (no PMID available)', 'extraction_confidence': 0.4}

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

710

Outgoing

659

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Metabolic Syndrome-Parkinson's Disease Axis Clinical Trial

derives from (13)

supports (58)

💬 Discussion